J&J Cypher Royalties To Drive SurModics Projected Growth Of 20-25% In 2002
This article was originally published in The Gray Sheet
Executive Summary
Royalties from Johnson & Johnson/Cordis' Cypher drug-eluting stent sales are expected to drive SurModics' fiscal 2002 top line growth "in the 20 to 25% range," SurModics says